HK1045812B - New use for budesonide and formoterol - Google Patents

New use for budesonide and formoterol Download PDF

Info

Publication number
HK1045812B
HK1045812B HK02107290.0A HK02107290A HK1045812B HK 1045812 B HK1045812 B HK 1045812B HK 02107290 A HK02107290 A HK 02107290A HK 1045812 B HK1045812 B HK 1045812B
Authority
HK
Hong Kong
Prior art keywords
use according
budesonide
active ingredient
fumarate dihydrate
formoterol fumarate
Prior art date
Application number
HK02107290.0A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1045812A1 (en
Inventor
Carl-Axel Bauer
Jan Trofast
Original Assignee
阿斯特拉曾尼卡有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408325&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1045812(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 阿斯特拉曾尼卡有限公司 filed Critical 阿斯特拉曾尼卡有限公司
Publication of HK1045812A1 publication Critical patent/HK1045812A1/en
Publication of HK1045812B publication Critical patent/HK1045812B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02107290.0A 1997-09-19 2002-10-03 New use for budesonide and formoterol HK1045812B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703407A SE9703407D0 (sv) 1997-09-19 1997-09-19 New use
SE9703407 1997-09-19

Publications (2)

Publication Number Publication Date
HK1045812A1 HK1045812A1 (en) 2002-12-13
HK1045812B true HK1045812B (en) 2006-12-22

Family

ID=20408325

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02107290.0A HK1045812B (en) 1997-09-19 2002-10-03 New use for budesonide and formoterol

Country Status (38)

Country Link
US (2) US7897646B2 (OSRAM)
EP (2) EP1210943B1 (OSRAM)
JP (1) JP2001517630A (OSRAM)
KR (1) KR20010024140A (OSRAM)
CN (1) CN1149998C (OSRAM)
AR (1) AR013506A1 (OSRAM)
AT (2) ATE222106T1 (OSRAM)
AU (1) AU757235B2 (OSRAM)
BR (1) BR9812325A (OSRAM)
CA (1) CA2302700C (OSRAM)
CY (1) CY1106156T1 (OSRAM)
CZ (1) CZ295250B6 (OSRAM)
DE (2) DE69807239T2 (OSRAM)
DK (2) DK1210943T3 (OSRAM)
EE (1) EE04297B1 (OSRAM)
ES (2) ES2266322T3 (OSRAM)
HK (1) HK1045812B (OSRAM)
HU (1) HUP0003848A2 (OSRAM)
ID (1) ID24838A (OSRAM)
IL (1) IL134773A (OSRAM)
IN (1) IN190791B (OSRAM)
IS (1) IS2715B (OSRAM)
MX (1) MXPA00002615A (OSRAM)
MY (1) MY127812A (OSRAM)
NO (1) NO327176B1 (OSRAM)
NZ (1) NZ503173A (OSRAM)
PL (1) PL190782B1 (OSRAM)
PT (2) PT1210943E (OSRAM)
RU (1) RU2199322C2 (OSRAM)
SA (1) SA98190773B1 (OSRAM)
SE (1) SE9703407D0 (OSRAM)
SI (2) SI1014993T1 (OSRAM)
SK (1) SK285330B6 (OSRAM)
TR (1) TR200000726T2 (OSRAM)
TW (1) TW546140B (OSRAM)
UA (1) UA72446C2 (OSRAM)
WO (1) WO1999015182A1 (OSRAM)
ZA (1) ZA988516B (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
CA2435982C (en) * 2001-02-06 2014-05-06 Innovata Biomed Limited Medicaments
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
EP1556018A1 (en) * 2002-09-30 2005-07-27 Acusphere, Inc. Sustained release porous microparticles for inhalation
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
PL1921919T3 (pl) 2005-07-14 2012-09-28 Lithera Inc Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej
EP1978933A2 (en) * 2005-12-15 2008-10-15 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for oral administration
US7913223B2 (en) * 2005-12-16 2011-03-22 Dialogic Corporation Method and system for development and use of a user-interface for operations, administration, maintenance and provisioning of a telecommunications system
GB0604141D0 (en) * 2006-03-01 2006-04-12 Arrow Int Ltd Nebulizer formulation
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EP3106149B1 (en) 2009-05-29 2019-11-20 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting beta-2 adrenergic receptor agonists and associated methods and systems
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2764867C (en) * 2009-06-09 2016-05-17 Elevation Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration
CN102000090A (zh) * 2009-08-31 2011-04-06 北京利乐生制药科技有限公司 一种以布地奈德与阿福特罗为活性成分的复方制剂
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
JP2013543897A (ja) 2010-11-24 2013-12-09 リセラ，インク． 脂肪症及び輪郭の膨れの美容処置のための、選択的な、親油性の、及び長時間作用性のベータアゴニストの単剤療法製剤、及び方法
US9585930B2 (en) 2011-03-20 2017-03-07 Trustees Of Boston University Therapeutic agent for emphysema and COPD
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
ITMI20130571A1 (it) * 2013-04-10 2014-10-11 Zambon Spa Composizione farmaceutica contenente budesonide e formoterolo
WO2015065220A1 (ru) * 2013-10-28 2015-05-07 Шолекс Девелопмент Гмбх Ингаляционный препарат для лечения бронхиальной астмы и хронической обструктивной болезни легких и способ его получения
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201321712D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Dry Powder Inhaler
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
EP3383366B2 (en) 2015-12-04 2024-06-05 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
WO2019241580A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
WO2021048171A1 (en) * 2019-09-10 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to improve phagocytosis
WO2021076701A1 (en) 2019-10-17 2021-04-22 Trustees Of Boston University Methods and compositions relating to lung function

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
GB2235626B (en) 1989-09-08 1994-02-09 Glaxo Group Ltd Inhalation medicaments for treating respiratory disorders
US5250286A (en) * 1990-05-07 1993-10-05 Aegis Technology, Inc. Treatment of chronic obstructive pulmonary disease (COPD) by inhalation of an imidazoline
PL164294B1 (pl) 1990-12-20 1994-07-29 Inst Farmaceutyczny Sposób otrzymywania diastereoizomeru /22R/-16a , 17a-butylidenodioksy-11 ß 21-dihydroksy-1,4-pregnadien-3,20-dionu PL
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
US5444521A (en) 1991-07-15 1995-08-22 Canon Kabushiki Kaisha Image fixing device capable of controlling heating overshoot
SK282826B6 (sk) * 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
EP1101493A3 (en) 1991-12-18 2004-01-14 AstraZeneca AB New combination of formoterol and budesonide
SE9404080L (sv) * 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
GB9519692D0 (en) * 1995-09-27 1995-11-29 Quillin Helen Atomising nozzle
WO1997021680A1 (en) * 1995-11-24 1997-06-19 Smithkline Beecham S.P.A. Quinoline derivatives
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
BR9810452A (pt) 1997-06-27 2000-09-05 Astra Ab Nova combinação de medicamentos contra asma
SE9703407D0 (sv) * 1997-09-19 1997-09-19 Astra Ab New use
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
SE9900834D0 (sv) 1999-03-09 1999-03-09 Astra Ab Novel combination

Also Published As

Publication number Publication date
AR013506A1 (es) 2000-12-27
NZ503173A (en) 2001-08-31
EP1014993A1 (en) 2000-07-05
CA2302700A1 (en) 1999-04-01
AU9192898A (en) 1999-04-12
EE200000145A (et) 2001-02-15
CZ295250B6 (cs) 2005-06-15
US20020042404A1 (en) 2002-04-11
SA98190773B1 (ar) 2006-10-02
SK285330B6 (sk) 2006-11-03
RU2199322C2 (ru) 2003-02-27
CA2302700C (en) 2010-11-23
US8461211B2 (en) 2013-06-11
ES2182357T3 (es) 2003-03-01
DE69807239T2 (de) 2003-04-10
US7897646B2 (en) 2011-03-01
NO20001401D0 (no) 2000-03-17
KR20010024140A (ko) 2001-03-26
IN190791B (OSRAM) 2003-08-23
JP2001517630A (ja) 2001-10-09
IL134773A (en) 2005-03-20
BR9812325A (pt) 2000-09-05
HK1045812A1 (en) 2002-12-13
HUP0003848A2 (hu) 2001-08-28
EE04297B1 (et) 2004-06-15
PT1014993E (pt) 2002-12-31
PL339295A1 (en) 2000-12-04
UA72446C2 (uk) 2005-03-15
NO20001401L (no) 2000-03-17
IS5407A (is) 2000-03-15
EP1014993B1 (en) 2002-08-14
DE69834955D1 (de) 2006-07-27
DE69807239D1 (de) 2002-09-19
DK1210943T3 (da) 2006-09-18
MY127812A (en) 2006-12-29
DK1014993T3 (da) 2002-11-11
TR200000726T2 (tr) 2000-09-21
ATE222106T1 (de) 2002-08-15
CN1149998C (zh) 2004-05-19
NO327176B1 (no) 2009-05-04
PL190782B1 (pl) 2006-01-31
SK3892000A3 (en) 2000-12-11
ATE329599T1 (de) 2006-07-15
SI1014993T1 (en) 2003-02-28
DE69834955T2 (de) 2007-01-25
WO1999015182A1 (en) 1999-04-01
PT1210943E (pt) 2006-09-29
ES2266322T3 (es) 2007-03-01
CY1106156T1 (el) 2011-06-08
IL134773A0 (en) 2001-04-30
SE9703407D0 (sv) 1997-09-19
MXPA00002615A (es) 2002-04-24
US20060189587A9 (en) 2006-08-24
IS2715B (is) 2011-02-15
TW546140B (en) 2003-08-11
ZA988516B (en) 1999-03-19
AU757235B2 (en) 2003-02-06
ID24838A (id) 2000-08-24
CZ2000950A3 (cs) 2000-06-14
US20110097282A1 (en) 2011-04-28
EP1210943A1 (en) 2002-06-05
CN1271287A (zh) 2000-10-25
EP1210943B1 (en) 2006-06-14
SI1210943T1 (sl) 2006-10-31

Similar Documents

Publication Publication Date Title
EP1210943B1 (en) New use for budesonide and formoterol
AU715319B2 (en) New combination
US9295644B2 (en) Methods and compositions for treating asthma
WO1999000134A1 (en) New combination of antiasthma medicaments
AU766637B2 (en) New use for budesonide and formoterol
MXPA98004357A (en) New combination

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20180908